RxDoctor Payments Data

Rajay Seudath, MD

Family Medicine · Tampa, FLNPI 1679968655

Payments from drug & device makers

$756in general payments, 2019–2025

Across 30 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$357
  • Amgen$79
  • Lilly USA, LLC$56
  • Pfizer$55
  • Bayer$52
  • GSK$50
  • plus $107 from 3 others

What the payments were for

  • Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$357
Amgen4$79
Lilly USA, LLC3$56
Pfizer3$55
Bayer2$52
GSK3$50
Johnson & Johnson3$46
Dexcom, Inc.2$37
Medtronic1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$756 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$9,190
Medicare patients
60
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide79$95,295
EliquisApixaban86$82,763
OzempicSemaglutide60$57,223
JardianceEmpagliflozin42$44,745
XareltoRivaroxaban40$33,727
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$25,913
FarxigaDapagliflozin Propanediol12$19,868
LinzessLinaclotide27$18,682
LantusInsulin Glargine,hum.Rec.Anlog45$8,023
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$6,262
Albuterol Sulfate HfaAlbuterol Sulfate201$6,118
Gabapentin226$3,964
Levothyroxine Sodium265$3,684
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen152$3,622
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm12$3,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$56$95,29579 claims
PfizerEliquis$55$82,76386 claims
AstraZenecaBreztri Aerosphere, Farxiga$357$45,78140 claims
Johnson & JohnsonXarelto$46$33,72740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →